Leukocyte removal for ulcerative colitis and Crohn’s disease

- For treatment of inflammatory bowel disease (IBD)
- Removal of leukocytes, which are implicated in inflammation (granulocyte, monocyte, lymphocyte)
- Easy handling - direct haemoperfusion -
- Gamma Sterilized / ETO Free
Features & Benefits

Features:
1. INNOVATIVE - LCAP therapy using the leukocyte removal filter, Cellsorba, removes leukocytes, which are implicated in inflammation (e.g. granulocyte, monocyte, lymphocyte). This principle can be used to influence the clinical status of patients in relation to their inflammatory state.
2. EASY - Simple, extracorporeal procedure, which requires approximately one hour per session.

Benefits:
CLINICAL EFFICACY - Remission and improvement were observed in 74% of active ulcerative colitis patients. (Matsumoto. et al. Ther Apher Dial. 12:484-90, 2008)

Structure
Whole blood flows into the cylindrical non-woven fabric. The non-woven fabric removes leukocytes through filtration and adhesion.

Blood flow

Circuit Diagram

Specifications

<table>
<thead>
<tr>
<th>Materials</th>
<th>Non-woven fabric made of polyethylene terephthalate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Column volume</td>
<td>170 mL</td>
</tr>
<tr>
<td>Column dimensions</td>
<td>200mm[L] - 45mm[D]</td>
</tr>
<tr>
<td>Sterilization</td>
<td>Gamma-Ray</td>
</tr>
</tbody>
</table>

Scanning Electron Micrograph pictures of leukocytes on the non-woven fabric of Cellsorba EX

x100

x500

Manufacturer:
ASAHI KASEI MEDICAL CO., LTD,
1-105 Kanda Hinocho, Chiyoda-ku, Tokyo 101-8191, Japan
TEL: +81-3-3296-3727 FAX: +81-3-3296-3722
URL: http://www.asahikasei-medical.com

Represented in Europe by:
ASAHI KASEI MEDICAL EUROPE GmbH
Herradonstrasse 1, 60528 Frankfurt am Main, Germany
TEL: +49 (0) 69 95 37 15 90 FAX: +49 (0) 69 95 37 16 90

Represented in America by:
ASAHI KASEI MEDICAL AMERICA INC.
3570 Winchester Road, Suite 101, Memphis, Tennessee 38118, USA
TEL: +1-901-362-6105 FAX: +1-901-362-6180

Copyright ©2012 Asahi Kasei Medical Co., Ltd. Printed in Japan No.2012.9.1589